深部热疗联合恩度、顺铂胸腔热灌注化疗对恶性胸腔积液患者免疫功能、肿瘤标志物影响及短期疗效的临床观察

doi:10.16389/j.cnki.cn42-1737/n.2024.05.008

江汉大学学报（自然科学版） ›› 2024, Vol. 52 ›› Issue (5): 71-78.doi: 10.16389/j.cnki.cn42-1737/n.2024.05.008

• 医学 • 上一篇

深部热疗联合恩度、顺铂胸腔热灌注化疗对恶性胸腔积液患者免疫功能、肿瘤标志物影响及短期疗效的临床观察

姜泓宇¹，马燕凌^*2

1. 江汉大学医学部，湖北武汉 430056；2. 湖北省第三人民医院肿瘤科，湖北武汉 430030

发布日期:2024-10-24
通讯作者: 马燕凌
作者简介:姜泓宇（1997— ），男，硕士生，研究方向：肿瘤学。

Clinical Observation on Effect of Deep Hyperthermia Combined with Endostar and Cisplatin Intrapleural Hyperthermic Chemotherapy on Immune Function and Tumor Markers and Short-term Curative Effect in Patients with Malignant Pleural Effusion

JIANG Hongyu ，MA Yanling

1. School of Medicine，Jianghan University，Wuhan 430056，Hubei，China；2. Department of Oncology， The Third People′s Hospital of Hubei Province，Wuhan 430030，Hubei，China

Published:2024-10-24
Contact: MA Yanling

摘要/Abstract

摘要： 目的 探讨深部热疗（deep hyperthermia）配合恩度（Endostar）、顺铂胸腔灌注化疗对恶性胸水患者免疫功能、肿瘤标志物的影响及其短期疗效。方法 选取 2020 年至 2023 年在湖北省第三人民医院肿瘤科治疗的恶性胸水患者 70 例，并将其随机分组成观察组与对照组，各 35 例。观察组采用深部热疗配合恩度（重组人血管内皮抑制素）、顺铂胸腔热灌注，对照组仅采用单纯恩度、顺铂胸腔热灌注。观察两组患者免疫相关指标（CD4+ 、CD8+ 、CD4+/CD8+）、肿瘤标志物（CEA、CA19-9、CA125）、短期疗效及疗程内的毒副反应（ADR）发生率，治疗结束后患者的生活质量改善率。结果 观察组的总体有效率（82. 86%）显著高于对照组（48. 57%）（P < 0. 05）。此外，在 CD4+ 和 CD4+/CD8+ 的对照中，观察组均显著大于对照组（P < 0. 05）；另外，两组患者的血清 CEA、CA125 和 CA19-9 水平都有所下降，而观察组的下降幅度明显大于对照组（P < 0. 05）；观察组的生活质量改善率（77. 13%）明显优于对照组（42. 85%）（P < 0. 05），两组不良反应（ADR）发生率无显著性差异（P > 0. 05）。结论 深部热疗与恩度、顺铂胸腔热灌注化疗相结合，可以提高患者的免疫功能，调节肿瘤标志物水平，对恶性胸水具有良好的短期疗效，能够使患者的生活质量得到有效的提升。

关键词: 恶性胸腔积液, 热灌注, 深部热疗, 肿瘤标志物, 肿瘤免疫

Abstract: Objective To investigate the effect of deep hyperthermia combined with Endostar and cisplatin intrapleural infusion chemotherapy on immune function and tumor markers and short- term curative effect in patients with malignant pleural effusion.Methods 70 patients with malignant pleural effusion treated in the oncology department of the Third People′s Hospital of Hubei Province from 2020 to 2023 were selected and randomly divided into an observation group and a control group，with 35 patients in each group. The observation group received deep hyperthermia combined with Endostatin （recombinant human Endostatin） and cisplatin intrapleural thermal perfusion， while the control group only received pure Endostatin and cisplatin intrapleural thermal perfusion. The immune-related indexes（CD4+，CD8+，CD4+/CD8+），tumor marker（CEA，CA19-9，CA125），shortterm curative effect，the occurrence rate of toxic and side effects during treatment，and the improvement rate of life quality after treatment were observed.Results The total effective rate of the observation group （82. 86%） was significantly higher than that of the control group （48. 57%）（P < 0. 05）. The observation group was significantly larger than the control group in terms of CD4+ and CD4+/CD8+ （P < 0. 05）. In addition，the serum levels of CEA，CA125，and CA19-9 in the two groups were decreased，but the decrease of the observation group was significantly greater than that of the control group（P < 0. 05）. The improvement rate of life quality in the observation group（77. 13%）was significantly better than that in the control group（42. 85%）（P < 0. 05），and there was no significant difference in the incidence of adverse reactions （ADR） between the two groups （P > 0. 05）.Conclusion Deep hyperthermia combined with Endostar and cisplatin thoracic hyperthermic perfusion chemotherapy can improve the immune function of patients，regulate the level of tumor markers，have a good short- term curative effect on malignant pleural effusion，and effectively improve the life quality of patients.

Key words: malignant pleural effusion, hyperthermic perfusion, deep hyperthermia, tumor markers, tumor immunity

中图分类号:

R734

姜泓宇，马燕凌. 深部热疗联合恩度、顺铂胸腔热灌注化疗对恶性胸腔积液患者免疫功能、肿瘤标志物影响及短期疗效的临床观察[J]. 江汉大学学报（自然科学版）, 2024, 52(5): 71-78.

JIANG Hongyu¹ ，MA Yanling^*2. Clinical Observation on Effect of Deep Hyperthermia Combined with Endostar and Cisplatin Intrapleural Hyperthermic Chemotherapy on Immune Function and Tumor Markers and Short-term Curative Effect in Patients with Malignant Pleural Effusion[J]. Journal of Jianghan University (Natural Science Edition), 2024, 52(5): 71-78.

[1]	蔡高平，余阳. 奥沙利铂联合腹腔热灌注化疗在进展期胃癌根治术后早期应用的安全性和疗效评估[J]. 江汉大学学报（自然科学版）, 2024, 52(1): 55-65.
[2]	盛津津，马燕凌. 恩度联合热灌注治疗恶性腹腔积液的研究进展[J]. 江汉大学学报（自然科学版）, 2022, 50(5): 81-89.
[3]	刘星宇，黄欢，李瑞，余俚瑶，颜琳，潘光鑫，卢豪，胡轶，陈宏伟，李雄，张淳. 宫颈癌肿瘤标志物在新辅助化疗中的应用[J]. 江汉大学学报（自然科学版）, 2019, 47(1): 87-91.
[4]	陈瑶，卢宏达. NSCLC 相关的恶性胸腔积液中VEGF 表达及临床意义研究进展[J]. 江汉大学学报（自然科学版）, 2018, 46(1): 87-96.
[5]	王传海,李承红. 肿瘤标志物联合检测在肺癌诊断中的意义[J]. 江汉大学学报（自然科学版）, 2009, 37(4): 87-89.

深部热疗联合恩度、顺铂胸腔热灌注化疗对恶性胸腔积液患者免疫功能、肿瘤标志物影响及短期疗效的临床观察

Clinical Observation on Effect of Deep Hyperthermia Combined with Endostar and Cisplatin Intrapleural Hyperthermic Chemotherapy on Immune Function and Tumor Markers and Short-term Curative Effect in Patients with Malignant Pleural Effusion

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价